In laboratories at New York University Abu Dhabi (NYUAD), a team of bioengineers is working on a technology that could one day challenge blockbuster weight-loss drugs like Ozempic — not with another injection, but with light.
The research, recently published in the peer-reviewed journal Advanced Materials Technologies, introduces a tiny ingestible LED capsule capable of emitting light inside the gut. While still in early-stage animal testing, the concept could eventually enable doctors to influence appetite, nutrient absorption, and digestive activity without pharmaceuticals.
Leading the project is Dr. Khalil Ramadi, Assistant Professor of Bioengineering and Director of NYUAD’s Laboratory for Advanced Neuroengineering and Translational Medicine.
His team’s long-term ambition is bold: create a non-drug, ingestible platform that can regulate hunger signals directly through neural pathways in the gut.
The Science Behind the Capsule
The capsule, fabricated using 3D printing, is designed to be swallowed and later expelled naturally. Once inside the body, it is powered wirelessly via magnetic fields — similar to the way wireless phone chargers operate — eliminating the need for onboard batteries.
In current experiments involving rats, the device emits light after activation. In future applications, specific gut neurons could be made light-sensitive through genetic techniques, allowing researchers to activate or suppress signals related to appetite or digestion.
This approach draws from the emerging field of optogenetics — a discipline that combines genetics and light to control cellular activity. While optogenetics is widely researched globally, the NYUAD study did not genetically modify animals during its initial phase.
Dr. Ramadi describes the technology as a platform, not just a single-use tool.
“You can transfer power to a very small component and then do different things with that power — activate neurons, release drugs, trigger switches,” he has explained in interviews. “That opens the door to multiple medical applications.”
A “Holy Grail” Alternative?
Weight-loss medications such as Ozempic — originally developed by Novo Nordisk for type 2 diabetes — have surged in global popularity due to their appetite-regulating properties. However, they require injections and can come with side effects.
The idea of influencing hunger or nutrient absorption directly through gut neural pathways represents what Dr. Ramadi calls a “holy grail” of ingestible bioelectronics.
The global anti-obesity drug market is projected to grow significantly over the next decade, according to healthcare market analyses cited by institutions such as McKinsey & Company. Yet pharmaceutical approaches are not the only path forward.
If bioelectronic devices can safely replicate or enhance appetite regulation mechanisms, they could redefine how obesity and metabolic disorders are treated.
Beyond Weight Loss
While weight management draws attention, the technology’s implications extend further.
One potential application involves treating constipation by stimulating gut contractions. Another possibility is selective nutrient absorption — potentially useful in managing metabolic diseases.
Dr. Mohamed Elsherif, the study’s lead author, emphasized that the capsule’s in-house fabrication using 3D printing eliminates the need for cleanroom manufacturing, potentially reducing production barriers.
The team’s next research steps may involve combining the capsule technology with optogenetic techniques to make specific gut cells light-responsive — though such applications remain experimental and years away from clinical trials.
Why This Innovation Matters for 2026
Healthcare innovation is shifting toward minimally invasive, precision-based treatments.
Instead of systemic drugs that affect the entire body, researchers are exploring localized interventions — targeting specific neural circuits, tissues, or pathways.
NYUAD’s LED capsule represents this shift.
By merging wireless power transfer, bioengineering, and optogenetics, the project positions Abu Dhabi within a growing field of ingestible medical devices.
If scaled successfully, such technology could:
- Reduce dependency on injectable weight-loss medications
- Enable personalized appetite regulation
- Expand non-pharmaceutical metabolic therapies
More broadly, it signals the UAE’s increasing role in translational medical research.
Daniel Carter covers UAE startups, venture capital, and AI innovation, delivering strategic, investigative reporting on emerging technology ecosystems.
